International Journal of Hematology最新文献_第4页

Myelodysplastic syndrome with ring chromosomes in a case of dehydrated hereditary stomatocytosis 1 (DHS1). 脱水遗传性口细胞增多症1 （DHS1）一例伴环染色体骨髓增生异常综合征。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-14 DOI: 10.1007/s12185-025-03967-5

Shinsaku Imashuku, Yasuhiro Kazuma, Kazuhisa Chonabayashi, Yutaka Shimazu, Junya Kanda, Yasuhito Nannya, Seishi Ogawa, Naoyuki Anzai

引用次数: 0

Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study. Vedolizumab用于预防低gi急性GVHD的日本3期石墨研究亚组分析。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-12 DOI: 10.1007/s12185-025-03955-9

Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, Yasuo Mori, Souichi Shiratori, Shin-Ichiro Fujiwara, Noriko Doki, Ken-Ichi Matsuoka, Yuta Katayama, Yi-Bin Chen, Yngvar Fløisand, Guillermo Rossiter, Johan Jansson, Ryou Nakaya, Takanori Teshima

{"title":"Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.","authors":"Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, Yasuo Mori, Souichi Shiratori, Shin-Ichiro Fujiwara, Noriko Doki, Ken-Ichi Matsuoka, Yuta Katayama, Yi-Bin Chen, Yngvar Fløisand, Guillermo Rossiter, Johan Jansson, Ryou Nakaya, Takanori Teshima","doi":"10.1007/s12185-025-03955-9","DOIUrl":"https://doi.org/10.1007/s12185-025-03955-9","url":null,"abstract":"In the randomized, double-blind, phase 3 GRAPHITE study (NCT03657160), anti-α4β7 integrin antibody vedolizumab showed greater efficacy than placebo for prevention of lower-gastrointestinal (GI) acute graft-versus-host disease (aGVHD) after unrelated allogenic hematopoietic stem cell transplantation (allo-HSCT). This post hoc analysis assessed the efficacy and safety of vedolizumab versus placebo for lower-GI aGVHD prevention in Japanese and non-Japanese patients, when added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate/mycophenolate mofetil + / - anti-thymocyte globulin [ATG]). The analysis included 35 (18 vedolizumab-treated, 17 placebo-treated) Japanese and 298 (150 vedolizumab-treated, 148 placebo-treated) non-Japanese patients. Lower-GI aGVHD-free survival by day + 180 after allo-HSCT (primary endpoint) was 94% in vedolizumab-treated versus 81% in placebo-treated Japanese patients (HR 0.36; 95% CI 0.03-4.01; P = 0.2) and 84% in vedolizumab-treated versus 70% in placebo-treated non-Japanese patients (HR 0.47; 95% CI 0.28-0.78; P = 0.002). The number of events for the 5 key secondary endpoints (lower-GI aGVHD-free and relapse-free survival, Grade C-D aGVHD-free survival, non-relapse mortality, overall survival, and Grade B-D aGVHD-free survival) by day + 180 was lower in vedolizumab- versus placebo-treated Japanese patients. No safety concerns were identified for vedolizumab use as lower-GI aGVHD prophylaxis in Japanese patients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice. 图西他汀治疗成人t细胞白血病/淋巴瘤的临床疗效。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-11 DOI: 10.1007/s12185-025-03963-9

Ayako Kamiunten, Takuro Kameda, Masaaki Sekine, Hiroshi Kawano, Takanori Toyama, Keiichi Akizuki, Noriaki Kawano, Kouichi Maeda, Seiichi Sato, Masanori Takeuchi, Junzo Ishizaki, Koshiro Nagamine, Ayuka Kuroki, Ryoma Ikeda, Kengo Matsumoto, Masayoshi Karasawa, Yuki Tahira, Taisuke Uchida, Haruko Shimoda, Tomonori Hidaka, Kiyoshi Yamashita, Hideki Yamaguchi, Yoko Kubuki, Kazuya Shimoda, Kotaro Shide

{"title":"Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.","authors":"Ayako Kamiunten, Takuro Kameda, Masaaki Sekine, Hiroshi Kawano, Takanori Toyama, Keiichi Akizuki, Noriaki Kawano, Kouichi Maeda, Seiichi Sato, Masanori Takeuchi, Junzo Ishizaki, Koshiro Nagamine, Ayuka Kuroki, Ryoma Ikeda, Kengo Matsumoto, Masayoshi Karasawa, Yuki Tahira, Taisuke Uchida, Haruko Shimoda, Tomonori Hidaka, Kiyoshi Yamashita, Hideki Yamaguchi, Yoko Kubuki, Kazuya Shimoda, Kotaro Shide","doi":"10.1007/s12185-025-03963-9","DOIUrl":"https://doi.org/10.1007/s12185-025-03963-9","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy with a poor prognosis. We conducted a retrospective study across six institutions in Miyazaki Prefecture, Japan, to assess the efficacy of tucidinostat in patients with relapsed/refractory ATL who had not undergone transplantation. Between October 2021 and July 2023, 24 patients aged 41 to 88 years (median, 73.4 years) who had undergone prior therapies, including intensive chemotherapy (79.2%) and mogamulizumab immunotherapy (79.2%), received tucidinostat. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated as key outcomes. ORR and DCR reached 54.2% and 91.7%, respectively. The median PFS was 3.95 months, and OS was 8.04 months, which were not inferior to the results of a phase IIb study. The influential factors for PFS were age ≥ 75 years and high soluble IL-2 receptor (sIL-2R) levels above 5000 U/mL at the start of treatment. Favorable patients without these factors achieved a PFS of 11.4 months. Treatment-related adverse events were mainly hematologic but were managed over the course of treatment. Our findings indicate that tucidinostat provides survival benefits in patients with relapsed/refractory ATL in clinical practice and highlight key clinical factors for better outcomes.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of conditioning intensity on late complications in AYA who underwent allogeneic HCT during childhood. 调节强度对儿童期接受同种异体HCT的AYA患者晚期并发症的影响。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-10 DOI: 10.1007/s12185-025-03961-x

Maiko Shimomura, Miho Ashiarai, Itaru Kato, Takahiro Kamiya, Nanami Taketomi, Tomoyuki Akita, Yasushi Orihashi, Hiroshi Kawaguchi, Katsutsugu Umeda

{"title":"Effect of conditioning intensity on late complications in AYA who underwent allogeneic HCT during childhood.","authors":"Maiko Shimomura, Miho Ashiarai, Itaru Kato, Takahiro Kamiya, Nanami Taketomi, Tomoyuki Akita, Yasushi Orihashi, Hiroshi Kawaguchi, Katsutsugu Umeda","doi":"10.1007/s12185-025-03961-x","DOIUrl":"https://doi.org/10.1007/s12185-025-03961-x","url":null,"abstract":"We retrospectively analyzed the effect of conditioning intensity on 22 late complications in 145 adolescent and young adults who underwent allogeneic hematopoietic cell transplantation (HCT) in childhood. Seventy-six patients received myeloablative conditioning (MAC), while 69 received reduced-intensity conditioning (RIC). Incidence rates of late complications (≥ 1), organ dysfunction, endocrine/metabolic abnormalities, and psychosocial issues in evaluable patients were 71.0%, 17.2%, 66.2%, and 9.0%, respectively. The prevalence of short stature, impaired glucose tolerance, dyslipidemia, and gonadal dysfunction was significantly higher in the MAC group than in the RIC group. Multivariate analyses identified conditioning regimen as an independent factor for gonadal dysfunction and impaired glucose tolerance, but not for short stature. In contrast, inverse probability of treatment weighting analysis revealed that the prevalence of not only gonadal dysfunction and impaired glucose tolerance, but also of short stature, was significantly higher in the MAC group than in the RIC group. The prevalence of organ dysfunction, secondary malignancies, and psychological issues did not differ significantly between the two groups. Reducing conditioning intensity significantly influenced various endocrine complications but not organ dysfunction or psychosocial issues. These findings will inform selection of optimal conditioning regimens and development of practical long-term follow-up systems for pediatric HCT recipients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes. 日本儿童RDD的回顾性全国调查：激酶通路基因突变的高流行率。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-10 DOI: 10.1007/s12185-025-03962-w

Takeshi Asano, Akira Morimoto, Atsuko Nakazawa, Takahiro Ueda, Chitose Ogawa, Naoki Sakata, Keisuke Sugimoto, Jotaro On, Yoshiyuki Takahashi, Naoki Otsuki, Yuichi Taneyama, Nobuyuki Hyakuna, Takashi Ishihara, Akihiko Matsumine, Yoko Shioda, Kenichi Sakamoto, Yozo Nakazawa, Takahiro Yasumi, Takehiko Doi, Yuhki Koga

{"title":"Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes.","authors":"Takeshi Asano, Akira Morimoto, Atsuko Nakazawa, Takahiro Ueda, Chitose Ogawa, Naoki Sakata, Keisuke Sugimoto, Jotaro On, Yoshiyuki Takahashi, Naoki Otsuki, Yuichi Taneyama, Nobuyuki Hyakuna, Takashi Ishihara, Akihiko Matsumine, Yoko Shioda, Kenichi Sakamoto, Yozo Nakazawa, Takahiro Yasumi, Takehiko Doi, Yuhki Koga","doi":"10.1007/s12185-025-03962-w","DOIUrl":"https://doi.org/10.1007/s12185-025-03962-w","url":null,"abstract":"Background: Rosai-Dorfman-Destombes disease (RDD) is a rare form of histiocytosis, characterized by the accumulation of S100 protein-positive and CD1a-negative histiocytes with emperipolesis. Recently, oncogenic mutations in mitogen-activated protein kinase pathway genes were reported in nearly half of RDD patients.Methods: We conducted a nationwide retrospective survey of childhood RDD in Japan.Results: We found nine patients (five boys and four girls) with a median age at diagnosis of 8 years and 3 months (range, 9 months to 15 years 5 months). Two patients had nodal lesions only, three had extra-nodal lesions only, and four had both. PD-L1 was expressed in all cases. Two were resolved without treatment. Three were treated with prednisolone, one with surgery and radiation, and three with chemotherapy. Two were complicated by glomerulonephritis. Somatic pathogenic mutations in the kinase pathway genes were found in five of the six patients analyzed (three in MAP2K1, one in KRAS, and one in TSC1). Two chemotherapy-resistant patients with MAP2K1 mutations responded to trametinib. Within a median follow-up of 4 years and 9 months, two died of disease.Conclusion: Most children with RDD carry mutations in the kinase pathway genes. Mutation analysis is suggested for patients with refractory disease.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma. 微小残留病阴性多发性骨髓瘤停药的回顾性分析。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-09 DOI: 10.1007/s12185-025-03966-6

Shuku Sato, Emi Sawazaki, Shun Tsunoda, Wataru Kamata, Tomiteru Togano, Yotaro Tamai

{"title":"Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma.","authors":"Shuku Sato, Emi Sawazaki, Shun Tsunoda, Wataru Kamata, Tomiteru Togano, Yotaro Tamai","doi":"10.1007/s12185-025-03966-6","DOIUrl":"https://doi.org/10.1007/s12185-025-03966-6","url":null,"abstract":"Background: The prognostic significance of minimal residual disease (MRD) negativity in multiple myeloma (MM) is well-established, and MRD negativity serves as a surrogate marker for treatment outcomes. However, in various clinical trials, achieving MRD negativity often leads to treatment continuation until disease progression. In real-world clinical practice, discontinuing treatment could lower healthcare costs and reduce adverse events.Methods: We retrospectively analyzed patients who reached MRD negativity and discontinued treatment.Results: A total of 39 multiple MM cases were included (17 eligible and 22 ineligible for autologous stem cell transplantation). The median time to next treatment was 42.4 months. Ten patients (25%) required additional treatment due to paraproteins or clinical relapse. Cumulative incidence of relapse at 12 and 48 months was 11.7% (95% confidence interval [CI], 4.5-28.2%) and 26.4% (95% CI, 12.8-49.6%), respectively. Multivariate analysis revealed that elevated lactate dehydrogenase (LDH) at first visit and t(4;14) were the only baseline factors significantly associated with worse outcomes. Eight patients (20%) with International Staging System (ISS) = I and with no risk factors (history of extramural disease, elevated LDH, high-risk cytogenetics) had no recurrence.Conclusion: Although treatment discontinuation in high-risk cases is potentially unsafe, low-risk cases demonstrate potential for treatment-free remission.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis. 阿那格列特在治疗原发性血小板增多症中的应用：一项系统回顾和荟萃分析。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-09 DOI: 10.1007/s12185-025-03959-5

Barbara Abreu Lopez, Joanne Arvelaez Pascucci, Safiya Mohamed Ramzy, Shivani Mehta, Sami Sami Daniel, Rishita Dave, Insiya Rampurawala, Lakshmi Sree Pugalenthi, Dhanuddara Kandambige, Victor Sebastian Arruarana, Ernesto Calderon Martinez

{"title":"Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.","authors":"Barbara Abreu Lopez, Joanne Arvelaez Pascucci, Safiya Mohamed Ramzy, Shivani Mehta, Sami Sami Daniel, Rishita Dave, Insiya Rampurawala, Lakshmi Sree Pugalenthi, Dhanuddara Kandambige, Victor Sebastian Arruarana, Ernesto Calderon Martinez","doi":"10.1007/s12185-025-03959-5","DOIUrl":"https://doi.org/10.1007/s12185-025-03959-5","url":null,"abstract":"Background: Essential thrombocythemia (ET) is a myeloproliferative neoplasm commonly treated with hydroxyurea, while anagrelide is a second-line option. Although anagrelide has thrombocyte-specific action, its comparative efficacy remains debated. This systematic review and meta-analysis aimed to measure platelet reduction, thromboembolic events, and adverse events.Methods: A systematic search of PubMed, Cochrane, Web of Science, Scopus, EMBASE, and CINAHL databases up to October 6, 2024, was conducted following the PRISMA guidelines. Randomized controlled trials and cohort studies comparing anagrelide and hydroxyurea were included.Results: Six studies with 1555 participants met the inclusion criteria. Anagrelide was associated with significantly lower platelet counts than hydroxyurea (MD - 65.22; 95% CI - 80.78 to - 49.66; p < 0.01; I2 = 0%), but no significant difference in thrombohemorrhagic events (RR 1.34; 95% CI 1.10 to 1.62; p < 0.01; I2 = 12.5%). In single-arm analysis, JAK-positive patients showed a higher incidence of thrombotic events (0.23; 95% CI 0.14-0.35) than JAK-negative patients (0.10; 95% CI 0.08-0.13). Adverse event rates varied (RR 1.37; 95% CI 0.37-5.12; I2 = 94.9%).Conclusion: Although comparative analyses against hydroxyurea have demonstrated the efficacy of anagrelide for platelet reduction in ET, its higher bleeding risk requires caution, especially in patients with risk factors. Further studies are needed to confirm long-term safety and refine dosing.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary pancreatic diffuse large B-cell lymphoma, appearing as an asymptomatic bulky mass with the duct-penetrating sign. 原发性胰腺弥漫性大b细胞淋巴瘤，表现为无症状的大块肿块，伴导管穿透征。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-06 DOI: 10.1007/s12185-025-03964-8

Naonori Harada

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: II. lymphoma-overview. 恶性血液病实用指南，2023:II。lymphoma-overview。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-04 DOI: 10.1007/s12185-025-03920-6

Ken Ohmachi

引用次数: 0

Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation. 异基因造血干细胞移植后多体腔积液对预后的影响。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-03 DOI: 10.1007/s12185-025-03949-7

Yasutaka Masuda, Akira Honda, Takashi Oyama, Yosuke Masamoto, Mineo Kurokawa

{"title":"Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation.","authors":"Yasutaka Masuda, Akira Honda, Takashi Oyama, Yosuke Masamoto, Mineo Kurokawa","doi":"10.1007/s12185-025-03949-7","DOIUrl":"https://doi.org/10.1007/s12185-025-03949-7","url":null,"abstract":"Fluid retention presenting as effusions in body cavities is sometimes encountered following allogeneic stem cell transplantation (allo-HSCT). It is unclear whether cavity effusions at independent sites may serve as cumulative correlates of fluid overload and whether a higher number of effusion sites are associated with a worse prognosis. Here, we comprehensively reviewed pleural, peritoneal, and pericardial effusions in 178 first allo-HSCT recipients retrospectively. A total of 123 (69.1%) patients developed effusions in any cavity. New pleural, peritoneal, and pericardial effusions were found after allo-HSCT in 106, 88, and 53 patients, at a median of 38.0 (range, 2-2950), 22.5 (range, 2-1324), and 40 (range, 2-945) days, respectively. The cumulative incidence at day 100 was 41.0%, 40.4%, and 20.8%, respectively. Of the 92 patients who presented with effusions by day 100, 28 patients presented with effusion in a single cavity, 39 in two cavities, and 25 in all three cavities. The 2-year overall survival rates of patients with effusions in zero, one, two, and three cavities by day 100 were 86.1%, 60.0%, 59.6%, and 18.8%, respectively, showing an additive adverse association with outcome. Prospective studies to further characterize fluid dynamics following allo-HSCT are warranted.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0